Thyroid I-131 Scan

Indications

To assess for the presence of and localization of any functioning residual, recurrent, or metastatic differentiated thyroid carcinoma after thyroidectomy or before/after I-131 ablation and for surveillance.

• Radiopharmaceutical:

- Diagnostic Imaging 1-4 mCi I-131 sodium iodine capsule administered by mouth
- ➤ Hyperthyroidism Ablation 5-15 mCi I-131 sodium iodine capsule administered by mouth
- > Thyroid Cancer Therapy 30-150 mCi I-131 sodium iodine capsule administered by mouth

• Patient Preparation:

> No specific preparation prior to radionuclide administration.

• Conflicting Examinations/Medications:

- > The following substances should be withheld for the indicated time frames as they can interfere with the uptake of radioiodine:
 - o levothyroxine (Synthroid) 4 wks
 - o liothyronine (Cytomel) 2 wks
 - o methimazole (Thiamazole) 3-7 days
 - o carbimazole 3-7 days
 - o propylthiouracil (PTU) 3-7 days

- o amiodarone 3-6 mths
- o iodine-containing medication/preparation 4 wks
- Lugol's / SSKI solution 4-6 wks
- o perchlorate 1 wk
- o kelp 4 wks
- ➤ Iodinated IV contrast musted be avoided for 3-4 wks.
- > A low-iodine diet should be followed for 1-2 weeks. Diet adequacy can be confirmed with an AM spot urine iodine level.
- ➤ TSH level should be ≥30 mIU/L accomplished by either thyroid hormone withdrawal or rhTSH (Thyrogen) stimulation.
- ➤ A patient may be maintained on T3 until 10–14 days prior to ablation to avoid severely symptomatic hypothyroidism.

• Pregnancy/Lactation:

- A negative urine pregnancy test is required in potentially-pregnant patients prior to I-131 administration. See Pregnant, Potentially Pregnant and Lactating Patients policy for specifics.
- ➤ Pregnancy should be avoided for 6 mths following I-131 administration.
- ➤ Breast feeding mothers should discontinue breast feeding 6 wks (preferably 3-6 mths) prior to I-131 administration and should not resume breast feeding the current child. Breast feeding can resume with the next child.

Imaging Technique:

- > Collimator medium energy high resolution
- > Photopeak 364 keV 15% window for I-131
- ➤ Image Preset Counts
 - O Whole Body Images 8-10 cm/min
 - o Static Images 10-20 mins/image
- ➤ Matrix Size 256 x 1024 (whole body), 256 x 256 (static)
- > <u>Zoom</u> 2.67
- Patient Positioning supine

• Imaging Views:

- > Imaging is obtained at 24 hrs and 48-72 hrs after diagnostic imaging doses and usually at 2-7 days after ablative doses.
- > Obtain anterior and posterior whole body images.
- > Obtain anterior static images centered on the neck (from nasopharynx to upper chest) with chin and sternal markers present.

Notes:

- Thyroglobulin (Tg) is used as a tumor marker in differentiated thyroid cancer after total thyroidectomy and radioiodine ablation. Typically a Tg level <1.0 ng/mL indicates remission, while a level >10 ng/mL indicates persistent disease.
- > Tg antibody is a class G immunoglobulin and can also be elevated in recurrent thyroid cancer.
- Metastatic thyroid cancer has lower density of and poorer functioning of Na-I symporters. TSH elevation over time is important to promote increased RAIU and retention in tumors. rhTSH-stimulated scans failed to detect remnant cancer localized to the

- thyroid bed in 17% of patients and metastatic disease in 29% in whom it was detected after thyroid hormone withdrawal.
- Tg elevation after rhTSH stimulation is 3–5 times less than that obtained after thyroid hormone withdrawal, which may result in suboptimal evaluation of post operative / post ablation disease burden.
- ➤ Diagnostic RAI imaging may reveal unexpected iodine-avid metastatic disease in 22%–35% of cases and change management in approximately 30%–50% of cases.
- Diagnostic RAI imaging is useful in determining the I-131 dose for ablation. Larger doses are usually given for treatment if regional or distant metastases are detected on the pre ablation scan.
- ➤ Only 1% of total thyroidectomies are truly total.